TL;DR: Rejuvenation Technologies Inc. is a Y Combinator Summer 2018 startup mRNA therapeutics to extend healthspan entering clinical trials, currently active with a team of 2.
mRNA therapeutics to extend healthspan entering clinical trials
Last verified:
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Built by LemStudio
Yes. Rejuvenation Technologies Inc. was funded by Y Combinator in the Summer 2018 batch. mRNA therapeutics to extend healthspan entering clinical trials
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stag…
Rejuvenation Technologies Inc. was part of Y Combinator's Summer 2018 batch.
Rejuvenation Technologies Inc. has a team of 2 people according to Y Combinator's directory.
Rejuvenation Technologies Inc. is currently listed as Active with a team of 2 in Y Combinator's directory.
Loading interactive view…